The presentation, scheduled for October 17–20, will be led by Professor Ren Mao of The First Affiliated Hospital at Sun Yat-sen University. The data set, identified as AS-UEG-2026-03820, outlines the 12-week results from the trial, which marks a significant milestone for the company's proprietary drug discovery platform. AC-101 targets the NOD signaling pathway, where dysregulation of the RIPK2 protein is known to drive inflammatory and autoimmune conditions.
Accro Bioscience to Unveil Phase 1b UC Trial Results in Barcelona
Clinical-stage biotechnology firm Accro Bioscience will present key efficacy and safety data from its Phase 1b proof-of-concept study for AC-101 at the upcoming UEG Week 2026 in Barcelona. The findings focus on the oral selective RIPK2 inhibitor as a potential induction therapy for moderate-to-severe ulcerative colitis.
Following successful Phase I studies in healthy volunteers across Australia and China, the company has completed its proof-of-concept testing in Chinese patients. With the U.S. FDA having already cleared an Investigational New Drug application for a Phase II clinical trial, these results serve as a critical bridge toward further global development. Accro Bioscience continues to focus on molecular mechanisms of regulatory cell death to address unmet needs in immune-mediated diseases.
Comments (0)
No comments yet. Be the first!